RIL
RDHL

Rothschild Investment LLC’s Redhill Biopharma RDHL Stock Holding History

Rothschild Investment LLC’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-17
Closed -$37 – 3490
2025
Q3 		$37 Buy
+17
New +$28 ﹤0.01% 3106

Other funds holding RDHL

YAG
Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.72% 1-Year Est. Return
YAL
Your Advocates Ltd Houston, Texas $350M AUM 21.03% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Rothschild Investment LLC's RDHL Position: Q4 2025 in Review

Rothschild Investment LLC sold out of Redhill Biopharma (RDHL) in Q4 2025, closing a stake of 17 shares — an estimated $37 sold.

Rothschild Investment LLC first reported a position in RDHL in Q3 2025 and held it in 1 quarter. The position peaked at $37 in Q3 2025. 17 funds tracked by Wall St. Rank hold RDHL as of Q4 2025.

  • Rothschild Investment LLC reported no remaining Redhill Biopharma position as of Q4 2025 after selling out during the quarter.
  • Rothschild Investment LLC sold 17 Redhill Biopharma shares in Q4 2025, an estimated $37.
  • Rothschild Investment LLC first reported a position in Redhill Biopharma in Q3 2025 and held it in 1 quarter.
  • Rothschild Investment LLC's Redhill Biopharma position peaked at $37 in Q3 2025.
  • 17 funds tracked by Wall St. Rank held Redhill Biopharma as of Q4 2025.

Based on Rothschild Investment LLC's 13F filing for Q4 2025, filed 10 Feb 2026.